You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameEprosartan
Accession NumberDB00876  (APRD00950)
TypeSmall Molecule
GroupsApproved
DescriptionEprosartan is an angiotensin II receptor antagonist used for the treatment of high blood pressure. It acts on the renin-angiotensin system in two ways to decrease total peripheral resistance. First, it blocks the binding of angiotensin II to AT1 receptors in vascular smooth muscle, causing vascular dilatation. Second, it inhibits sympathetic norepinephrine production, further reducing blood pressure.
Structure
Thumb
Synonyms
(e)-2-Butyl-1-(P-carboxybenzyl)-alpha-2-thenylimidazole-5-acrylic acid
(e)-3-[2-N-Butyl-1-{(4-carboxyphenyl)methyl}-1H-imidazol-5-yl]-2-(2-thienyl)methyl-2-propenoic acid
(e)-Alpha{[2-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazole-5-yl]methylene}-2-thiopheneproprionic acid
Eprosartan
Éprosartan
Eprosartan
Eprosartanum
External Identifiers
  • SKF 108566
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Tevetentablet400 mg/1oralAbb Vie Inc.2010-05-242016-04-05Us
Tevetentablet600 mgoralBgp Pharma Ulc2001-05-25Not applicableCanada
Tevetentablet600 mg/1oralAbb Vie Inc.2010-05-242016-04-05Us
Tevetentablet400 mgoralBgp Pharma Ulc2000-09-08Not applicableCanada
Teveten Tablets 300 mgtablet300 mgoralSolvay Pharma Inc2000-09-082003-01-02Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Eprosartan Mesylatetablet, film coated600 mg/1oralMylan Pharmaceuticals Inc.2011-12-20Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
EprozarINTAS Pharmaceuticals
FuturanMerck
Brand mixtures
NameLabellerIngredients
Teveten HctAbb Vie Inc.
Teveten PlusBgp Pharma Ulc
Salts
Name/CASStructureProperties
Eprosartan mesylate
ThumbNot applicableDBSALT000927
Categories
UNII2KH13Z0S0Y
CAS number133040-01-4
WeightAverage: 424.513
Monoisotopic: 424.145677956
Chemical FormulaC23H24N2O4S
InChI KeyInChIKey=OROAFUQRIXKEMV-LDADJPATSA-N
InChI
InChI=1S/C23H24N2O4S/c1-2-3-6-21-24-14-19(12-18(23(28)29)13-20-5-4-11-30-20)25(21)15-16-7-9-17(10-8-16)22(26)27/h4-5,7-12,14H,2-3,6,13,15H2,1H3,(H,26,27)(H,28,29)/b18-12+
IUPAC Name
4-({2-butyl-5-[(1E)-2-carboxy-2-(thiophen-2-ylmethyl)eth-1-en-1-yl]-1H-imidazol-1-yl}methyl)benzoic acid
SMILES
CCCCC1=NC=C(\C=C(/CC2=CC=CS2)C(O)=O)N1CC1=CC=C(C=C1)C(O)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzoic acids. These are organic Compounds containing a benzene ring which bears at least one carboxyl group.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzoic acids and derivatives
Direct ParentBenzoic acids
Alternative Parents
Substituents
  • Benzoic acid
  • Trisubstituted imidazole
  • Phenylmethylamine
  • Imidazolyl carboxylic acid derivative
  • Benzoyl
  • 1,2,5-trisubstituted-imidazole
  • N-substituted imidazole
  • Dicarboxylic acid or derivatives
  • Heteroaromatic compound
  • Thiophene
  • Imidazole
  • Azole
  • Azacycle
  • Organoheterocyclic compound
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the management of hypertension alone or in combination with other classes of antihypertensive agents. Also used as a first-line agent in the treatment of diabetic nephropathy, as well as a second-line agent in the treatment of congestive heart failure (only in those intolerant of ACE inhibitors).
PharmacodynamicsAngiotensin II, the principal pressor agent of the renin-angiotensin system, is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme [kininase II]. It is responsible for effects such as vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Eprosartan selectively blocks the binding of angiotensin II to the AT1 receptor, which in turn leads to multiple effects including vasodilation, a reduction in the secretion of vasopressin, and reduction in the production and secretion of aldosterone. The resulting effect is a decrease in blood pressure.
Mechanism of actionEprosartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor found in many tissues (e.g., vascular smooth muscle, adrenal gland). There is also an AT2 receptor found in many tissues but it is not known to be associated with cardiovascular homeostasis. Eprosartan does not exhibit any partial agonist activity at the AT1 receptor. Its affinity for the AT1 receptor is 1,000 times greater than for the AT2 receptor. In vitro binding studies indicate that eprosartan is a reversible, competitive inhibitor of the AT1 receptor. Eprosartan has also been shown to bind to AT1 receptors both presynaptically and synaptically. Its action on presynaptic AT1 receptors results in the inhibition of sympathetically stimulated noradrenaline release. Unlike ACE inhibitors, eprosartan and other ARBs do not interfere with response to bradykinins and substance P, which allows for the absence of adverse effects that are present in ACE inhibitors (eg. dry cough).
Related Articles
AbsorptionAbsolute bioavailability following a single 300 mg oral dose of eprosartan is approximately 13%. Administering eprosartan with food delays absorption.
Volume of distributionNot Available
Protein bindingPlasma protein binding of eprosartan is high (approximately 98%) and constant over the concentration range achieved with therapeutic doses.
Metabolism

Eprosartan is not metabolized by the cytochrome P450 system. It is mainly eliminated as unchanged drug. Less than 2% of an oral dose is excreted in the urine as a glucuronide.

Route of eliminationNot Available
Half lifeThe terminal elimination half-life of eprosartan following oral administration is typically 5 to 9 hours.
ClearanceNot Available
ToxicityThere was no mortality in rats and mice receiving oral doses of up to 3000 mg eprosartan/kg and in dogs receiving oral doses of up to 1000 mg eprosartan/kg.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Eprosartan Action PathwayDrug actionSMP00159
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9863
Blood Brain Barrier-0.6931
Caco-2 permeable-0.6261
P-glycoprotein substrateSubstrate0.8011
P-glycoprotein inhibitor INon-inhibitor0.8577
P-glycoprotein inhibitor IINon-inhibitor0.9574
Renal organic cation transporterNon-inhibitor0.7673
CYP450 2C9 substrateNon-substrate0.7897
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.7557
CYP450 1A2 substrateNon-inhibitor0.5798
CYP450 2C9 inhibitorNon-inhibitor0.6617
CYP450 2D6 inhibitorNon-inhibitor0.8325
CYP450 2C19 inhibitorNon-inhibitor0.6234
CYP450 3A4 inhibitorNon-inhibitor0.6086
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.644
Ames testNon AMES toxic0.7313
CarcinogenicityNon-carcinogens0.9454
BiodegradationNot ready biodegradable0.6117
Rat acute toxicity2.4288 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9464
hERG inhibition (predictor II)Non-inhibitor0.8827
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Abbott laboratories
Packagers
Dosage forms
FormRouteStrength
Tablet, film coatedoral600 mg/1
Tabletoral400 mg
Tabletoral400 mg/1
Tabletoral600 mg
Tabletoral600 mg/1
Tabletoral
Tabletoral300 mg
Prices
Unit descriptionCostUnit
Teveten hct 600-12.5 mg tablet3.52USD tablet
Teveten hct 600-25 mg tablet3.42USD tablet
Teveten 600 mg tablet3.19USD tablet
Teveten 400 mg tablet2.83USD tablet
Teveten 400 mg tiltab1.24USD tablet
Teveten 600 mg Tablet1.18USD tablet
Teveten 400 mg Tablet0.79USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2115170 No2004-05-252012-08-12Canada
CA2250395 No2005-09-062017-03-26Canada
US5185351 No1993-02-092010-02-09Us
US5656650 No1994-08-122014-08-12Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point248-250 °C (mesylate form)Not Available
water solubilityInsoluble (mesylate form)Not Available
logP3.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00866 mg/mLALOGPS
logP3.57ALOGPS
logP3.8ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)3.63ChemAxon
pKa (Strongest Basic)6.93ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area92.42 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity117.02 m3·mol-1ChemAxon
Polarizability45.29 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Richard T. Matsuoka, Peng Liu, “Process for preparing eprosartan using regioselective protection of 2,4-disubstituted-imidazole intermediates.” U.S. Patent US6294675, issued June, 1992.

US6294675
General References
  1. Ruilope L, Jager B, Prichard B: Eprosartan versus enalapril in elderly patients with hypertension: a double-blind, randomized trial. Blood Press. 2001;10(4):223-9. [PubMed:11800061 ]
  2. Hedner T: The clinical profile of the angiotensin II receptor blocker eprosartan. J Hypertens Suppl. 2002 Jun;20(5):S33-8. [PubMed:12184062 ]
  3. Puig JG, Lopez MA, Bueso TS, Bernardino JI, Jimenez RT: Clinical profile of eprosartan. Cardiovasc Drugs Ther. 2002 Dec;16(6):543-9. [PubMed:12766389 ]
  4. Ruilope L, Jager B: Eprosartan for the treatment of hypertension. Expert Opin Pharmacother. 2003 Jan;4(1):107-14. [PubMed:12517247 ]
  5. de la Sierra A, Ram CV: Introduction: The pharmacological profile of eprosartan--implications for cerebrovascular and cardiovascular risk reduction. Curr Med Res Opin. 2007 Nov;23 Suppl 5:S1-3. doi: 10.1185/030079907X260692. [PubMed:18093407 ]
  6. Blankestijn PJ, Rupp H: Clinical profile of eprosartan: a different angiotensin II receptor blocker. Cardiovasc Hematol Agents Med Chem. 2008 Oct;6(4):253-7. [PubMed:18855637 ]
External Links
ATC CodesC09CA02C09DA02
AHFS Codes
  • 24:32.08
PDB EntriesNot Available
FDA labelDownload (1.09 MB)
MSDSNot Available
Interactions
Drug Interactions
Drug
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Eprosartan.
AcebutololEprosartan may increase the hypotensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Eprosartan is combined with Aceclofenac.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Eprosartan.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Eprosartan is combined with Acetylsalicylic acid.
AdapaleneThe risk or severity of adverse effects can be increased when Eprosartan is combined with Adapalene.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Eprosartan.
AlfuzosinAlfuzosin may increase the hypotensive activities of Eprosartan.
AliskirenEprosartan may increase the hypotensive activities of Aliskiren.
AlprenololAlprenolol may increase the hypotensive activities of Eprosartan.
AmbrisentanEprosartan may increase the hypotensive activities of Ambrisentan.
AmifostineEprosartan may increase the hypotensive activities of Amifostine.
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Eprosartan.
AmlodipineAmlodipine may increase the hypotensive activities of Eprosartan.
AmobarbitalAmobarbital may increase the hypotensive activities of Eprosartan.
Amyl NitriteThe risk or severity of adverse effects can be increased when Eprosartan is combined with Amyl Nitrite.
AntipyrineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Antipyrine.
ApraclonidineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Apraclonidine.
ApremilastThe risk or severity of adverse effects can be increased when Eprosartan is combined with Apremilast.
ArdeparinArdeparin may increase the hyperkalemic activities of Eprosartan.
AripiprazoleAripiprazole may increase the hypotensive activities of Eprosartan.
AtenololAtenolol may increase the hypotensive activities of Eprosartan.
AzapropazoneThe risk or severity of adverse effects can be increased when Eprosartan is combined with Azapropazone.
AzelastineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Azelastine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Eprosartan is combined with Azilsartan medoxomil.
BalsalazideThe risk or severity of adverse effects can be increased when Eprosartan is combined with Balsalazide.
BarbitalBarbital may increase the hypotensive activities of Eprosartan.
BemiparinBemiparin may increase the hyperkalemic activities of Eprosartan.
BenazeprilBenazepril may increase the hypotensive activities of Eprosartan.
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Eprosartan.
BenmoxinBenmoxin may increase the hypotensive activities of Eprosartan.
BenoxaprofenThe risk or severity of adverse effects can be increased when Eprosartan is combined with Benoxaprofen.
BepridilEprosartan may increase the hypotensive activities of Bepridil.
BetaxololBetaxolol may increase the hypotensive activities of Eprosartan.
BethanidineBethanidine may increase the hypotensive activities of Eprosartan.
BimatoprostEprosartan may increase the hypotensive activities of Bimatoprost.
BisoprololBisoprolol may increase the hypotensive activities of Eprosartan.
BosentanBosentan may increase the hypotensive activities of Eprosartan.
BretyliumEprosartan may increase the hypotensive activities of Bretylium.
BrimonidineEprosartan may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Eprosartan.
BromfenacThe risk or severity of adverse effects can be increased when Eprosartan is combined with Bromfenac.
BumetanideThe risk or severity of adverse effects can be increased when Eprosartan is combined with Bumetanide.
BupranololEprosartan may increase the hypotensive activities of Bupranolol.
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Eprosartan.
CanagliflozinThe risk or severity of adverse effects can be increased when Eprosartan is combined with Canagliflozin.
CandesartanCandesartan may increase the hypotensive activities of Eprosartan.
CandoxatrilCandoxatril may increase the hypotensive activities of Eprosartan.
CaptoprilEprosartan may increase the hypotensive activities of Captopril.
CaroxazoneCaroxazone may increase the hypotensive activities of Eprosartan.
CarprofenThe risk or severity of adverse effects can be increased when Eprosartan is combined with Carprofen.
CarteololCarteolol may increase the hypotensive activities of Eprosartan.
CarvedilolEprosartan may increase the hypotensive activities of Carvedilol.
CastanospermineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Castanospermine.
CelecoxibThe risk or severity of adverse effects can be increased when Eprosartan is combined with Celecoxib.
CeliprololEprosartan may increase the hypotensive activities of Celiprolol.
CertoparinCertoparin may increase the hyperkalemic activities of Eprosartan.
ChloroquineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Chloroquine.
ChlorothiazideEprosartan may increase the hypotensive activities of Chlorothiazide.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Eprosartan.
CilazaprilEprosartan may increase the hypotensive activities of Cilazapril.
CiprofloxacinEprosartan may increase the arrhythmogenic activities of Ciprofloxacin.
ClevidipineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Clevidipine.
ClonidineClonidine may increase the hypotensive activities of Eprosartan.
ClonixinThe risk or severity of adverse effects can be increased when Eprosartan is combined with Clonixin.
CryptenamineCryptenamine may increase the hypotensive activities of Eprosartan.
CyclosporineEprosartan may increase the hyperkalemic activities of Cyclosporine.
CyclothiazideCyclothiazide may increase the hypotensive activities of Eprosartan.
D-LimoneneThe risk or severity of adverse effects can be increased when Eprosartan is combined with D-Limonene.
DalteparinDalteparin may increase the hyperkalemic activities of Eprosartan.
DapagliflozinThe risk or severity of adverse effects can be increased when Eprosartan is combined with Dapagliflozin.
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Eprosartan.
DebrisoquinEprosartan may increase the hypotensive activities of Debrisoquin.
DeserpidineEprosartan may increase the hypotensive activities of Deserpidine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Eprosartan.
DiazoxideDiazoxide may increase the hypotensive activities of Eprosartan.
DiclofenacThe risk or severity of adverse effects can be increased when Eprosartan is combined with Diclofenac.
DiclofenamideThe risk or severity of adverse effects can be increased when Eprosartan is combined with Diclofenamide.
DiflunisalThe risk or severity of adverse effects can be increased when Eprosartan is combined with Diflunisal.
DiltiazemDiltiazem may increase the hypotensive activities of Eprosartan.
DinutuximabThe risk or severity of adverse effects can be increased when Eprosartan is combined with Dinutuximab.
DipyridamoleThe risk or severity of adverse effects can be increased when Eprosartan is combined with Dipyridamole.
DorzolamideDorzolamide may increase the hypotensive activities of Eprosartan.
DoxazosinDoxazosin may increase the hypotensive activities of Eprosartan.
DrospirenoneEprosartan may increase the hyperkalemic activities of Drospirenone.
DroxicamThe risk or severity of adverse effects can be increased when Eprosartan is combined with Droxicam.
DuloxetineEprosartan may increase the orthostatic hypotensive activities of Duloxetine.
EfonidipineEprosartan may increase the hypotensive activities of Efonidipine.
EmpagliflozinThe risk or severity of adverse effects can be increased when Eprosartan is combined with Empagliflozin.
EnalaprilEnalapril may increase the hypotensive activities of Eprosartan.
EnalaprilatEprosartan may increase the hypotensive activities of Enalaprilat.
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Eprosartan.
EpirizoleThe risk or severity of adverse effects can be increased when Eprosartan is combined with Epirizole.
EplerenoneEplerenone may increase the hyperkalemic activities of Eprosartan.
EplerenoneThe risk or severity of adverse effects can be increased when Eprosartan is combined with Eplerenone.
EpoprostenolEprosartan may increase the hypotensive activities of Epoprostenol.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Eprosartan.
Etacrynic acidThe risk or severity of adverse effects can be increased when Eprosartan is combined with Etacrynic acid.
EtanerceptThe risk or severity of adverse effects can be increased when Eprosartan is combined with Etanercept.
EtodolacThe risk or severity of adverse effects can be increased when Eprosartan is combined with Etodolac.
EtofenamateThe risk or severity of adverse effects can be increased when Eprosartan is combined with Etofenamate.
EtoricoxibThe risk or severity of adverse effects can be increased when Eprosartan is combined with Etoricoxib.
Evening primrose oilThe risk or severity of adverse effects can be increased when Eprosartan is combined with Evening primrose oil.
exisulindThe risk or severity of adverse effects can be increased when Eprosartan is combined with exisulind.
FelodipineEprosartan may increase the hypotensive activities of Felodipine.
FenbufenThe risk or severity of adverse effects can be increased when Eprosartan is combined with Fenbufen.
FenoldopamFenoldopam may increase the hypotensive activities of Eprosartan.
FenoprofenThe risk or severity of adverse effects can be increased when Eprosartan is combined with Fenoprofen.
FloctafenineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Floctafenine.
FlunixinThe risk or severity of adverse effects can be increased when Eprosartan is combined with Flunixin.
FlurbiprofenThe risk or severity of adverse effects can be increased when Eprosartan is combined with Flurbiprofen.
FosinoprilFosinopril may increase the hypotensive activities of Eprosartan.
FurazolidoneFurazolidone may increase the hypotensive activities of Eprosartan.
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Eprosartan.
GuanabenzGuanabenz may increase the hypotensive activities of Eprosartan.
GuanadrelGuanadrel may increase the hypotensive activities of Eprosartan.
GuanethidineEprosartan may increase the hypotensive activities of Guanethidine.
GuanfacineEprosartan may increase the hypotensive activities of Guanfacine.
HeparinHeparin may increase the hyperkalemic activities of Eprosartan.
HexamethoniumEprosartan may increase the hypotensive activities of Hexamethonium.
HexobarbitalHexobarbital may increase the hypotensive activities of Eprosartan.
HMPL-004The risk or severity of adverse effects can be increased when Eprosartan is combined with HMPL-004.
HydracarbazineHydracarbazine may increase the hypotensive activities of Eprosartan.
HydralazineEprosartan may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideEprosartan may increase the hypotensive activities of Hydrochlorothiazide.
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Eprosartan.
IbuprofenThe risk or severity of adverse effects can be increased when Eprosartan is combined with Ibuprofen.
IbuproxamThe risk or severity of adverse effects can be increased when Eprosartan is combined with Ibuproxam.
IcatibantThe risk or severity of adverse effects can be increased when Eprosartan is combined with Icatibant.
IloprostIloprost may increase the hypotensive activities of Eprosartan.
IndapamideIndapamide may increase the hypotensive activities of Eprosartan.
IndenololEprosartan may increase the hypotensive activities of Indenolol.
IndomethacinThe risk or severity of adverse effects can be increased when Eprosartan is combined with Indomethacin.
IndoprofenThe risk or severity of adverse effects can be increased when Eprosartan is combined with Indoprofen.
IndoraminEprosartan may increase the hypotensive activities of Indoramin.
IproclozideIproclozide may increase the hypotensive activities of Eprosartan.
IproniazidIproniazid may increase the hypotensive activities of Eprosartan.
IrbesartanEprosartan may increase the hypotensive activities of Irbesartan.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Eprosartan.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Eprosartan is combined with Isosorbide Dinitrate.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Eprosartan is combined with Isosorbide Mononitrate.
IsoxicamThe risk or severity of adverse effects can be increased when Eprosartan is combined with Isoxicam.
IsoxsuprineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Isoxsuprine.
IsradipineIsradipine may increase the hypotensive activities of Eprosartan.
KebuzoneThe risk or severity of adverse effects can be increased when Eprosartan is combined with Kebuzone.
KetoprofenThe risk or severity of adverse effects can be increased when Eprosartan is combined with Ketoprofen.
KetorolacThe risk or severity of adverse effects can be increased when Eprosartan is combined with Ketorolac.
LabetalolLabetalol may increase the hypotensive activities of Eprosartan.
LacidipineEprosartan may increase the hypotensive activities of Lacidipine.
LatanoprostLatanoprost may increase the hypotensive activities of Eprosartan.
LeflunomideThe risk or severity of adverse effects can be increased when Eprosartan is combined with Leflunomide.
LercanidipineLercanidipine may increase the hypotensive activities of Eprosartan.
LevobunololThe risk or severity of adverse effects can be increased when Eprosartan is combined with Levobunolol.
LevodopaEprosartan may increase the orthostatic hypotensive activities of Levodopa.
LisinoprilLisinopril may increase the hypotensive activities of Eprosartan.
LithiumThe serum concentration of Lithium can be increased when it is combined with Eprosartan.
LofexidineEprosartan may increase the hypotensive activities of Lofexidine.
LornoxicamThe risk or severity of adverse effects can be increased when Eprosartan is combined with Lornoxicam.
LosartanLosartan may increase the hypotensive activities of Eprosartan.
LoxoprofenThe risk or severity of adverse effects can be increased when Eprosartan is combined with Loxoprofen.
LumiracoxibThe risk or severity of adverse effects can be increased when Eprosartan is combined with Lumiracoxib.
MacitentanEprosartan may increase the hypotensive activities of Macitentan.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Eprosartan is combined with Magnesium salicylate.
ManidipineEprosartan may increase the hypotensive activities of Manidipine.
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Eprosartan.
MasoprocolThe risk or severity of adverse effects can be increased when Eprosartan is combined with Masoprocol.
MebanazineMebanazine may increase the hypotensive activities of Eprosartan.
MecamylamineMecamylamine may increase the hypotensive activities of Eprosartan.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Eprosartan is combined with Meclofenamic acid.
Mefenamic acidThe risk or severity of adverse effects can be increased when Eprosartan is combined with Mefenamic acid.
MeloxicamThe risk or severity of adverse effects can be increased when Eprosartan is combined with Meloxicam.
MesalazineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Mesalazine.
MetamizoleThe risk or severity of adverse effects can be increased when Eprosartan is combined with Metamizole.
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Eprosartan.
MethohexitalMethohexital may increase the hypotensive activities of Eprosartan.
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Eprosartan.
MethyldopaEprosartan may increase the hypotensive activities of Methyldopa.
Methylene blueMethylene blue may increase the hypotensive activities of Eprosartan.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Eprosartan.
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Eprosartan.
MetipranololEprosartan may increase the hypotensive activities of Metipranolol.
MetolazoneMetolazone may increase the hypotensive activities of Eprosartan.
MetoprololMetoprolol may increase the hypotensive activities of Eprosartan.
MibefradilEprosartan may increase the hypotensive activities of Mibefradil.
MinaprineMinaprine may increase the hypotensive activities of Eprosartan.
MinoxidilMinoxidil may increase the hypotensive activities of Eprosartan.
MoclobemideMoclobemide may increase the hypotensive activities of Eprosartan.
MoexiprilMoexipril may increase the hypotensive activities of Eprosartan.
MolsidomineMolsidomine may increase the hypotensive activities of Eprosartan.
MoxonidineEprosartan may increase the hypotensive activities of Moxonidine.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Eprosartan is combined with Mycophenolate mofetil.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Eprosartan is combined with Mycophenolic acid.
NabumetoneThe risk or severity of adverse effects can be increased when Eprosartan is combined with Nabumetone.
NadololEprosartan may increase the hypotensive activities of Nadolol.
NadroparinNadroparin may increase the hyperkalemic activities of Eprosartan.
NaftifineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Naftifine.
NaproxenThe risk or severity of adverse effects can be increased when Eprosartan is combined with Naproxen.
NCX 4016The risk or severity of adverse effects can be increased when Eprosartan is combined with NCX 4016.
NebivololEprosartan may increase the hypotensive activities of Nebivolol.
NepafenacThe risk or severity of adverse effects can be increased when Eprosartan is combined with Nepafenac.
NesiritideThe risk or severity of adverse effects can be increased when Eprosartan is combined with Nesiritide.
NialamideNialamide may increase the hypotensive activities of Eprosartan.
NicardipineNicardipine may increase the hypotensive activities of Eprosartan.
NicorandilNicorandil may increase the hypotensive activities of Eprosartan.
NifedipineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Nifedipine.
Niflumic AcidThe risk or severity of adverse effects can be increased when Eprosartan is combined with Niflumic Acid.
NiguldipineEprosartan may increase the hypotensive activities of Niguldipine.
NilvadipineEprosartan may increase the hypotensive activities of Nilvadipine.
NimesulideThe risk or severity of adverse effects can be increased when Eprosartan is combined with Nimesulide.
NimodipineNimodipine may increase the hypotensive activities of Eprosartan.
NisoldipineNisoldipine may increase the hypotensive activities of Eprosartan.
NitrendipineEprosartan may increase the hypotensive activities of Nitrendipine.
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Eprosartan.
NitroprussideNitroprusside may increase the hypotensive activities of Eprosartan.
ObinutuzumabEprosartan may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Eprosartan.
OlmesartanOlmesartan may increase the hypotensive activities of Eprosartan.
OlopatadineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Olopatadine.
OlsalazineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Olsalazine.
OmapatrilatEprosartan may increase the hypotensive activities of Omapatrilat.
OrgoteinThe risk or severity of adverse effects can be increased when Eprosartan is combined with Orgotein.
OxaprozinThe risk or severity of adverse effects can be increased when Eprosartan is combined with Oxaprozin.
OxprenololEprosartan may increase the hypotensive activities of Oxprenolol.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Eprosartan is combined with Oxyphenbutazone.
PapaverineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Papaverine.
ParecoxibThe risk or severity of adverse effects can be increased when Eprosartan is combined with Parecoxib.
PargylineEprosartan may increase the hypotensive activities of Pargyline.
ParnaparinParnaparin may increase the hyperkalemic activities of Eprosartan.
PenbutololEprosartan may increase the hypotensive activities of Penbutolol.
PentobarbitalPentobarbital may increase the hypotensive activities of Eprosartan.
PentoliniumEprosartan may increase the hypotensive activities of Pentolinium.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Eprosartan.
PerindoprilPerindopril may increase the hypotensive activities of Eprosartan.
PhenelzinePhenelzine may increase the hypotensive activities of Eprosartan.
PheniprazinePheniprazine may increase the hypotensive activities of Eprosartan.
PhenobarbitalPhenobarbital may increase the hypotensive activities of Eprosartan.
PhenoxybenzamineEprosartan may increase the hypotensive activities of Phenoxybenzamine.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Eprosartan.
PhentolaminePhentolamine may increase the hypotensive activities of Eprosartan.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Eprosartan is combined with Phenylbutazone.
PimecrolimusThe risk or severity of adverse effects can be increased when Eprosartan is combined with Pimecrolimus.
PinacidilEprosartan may increase the hypotensive activities of Pinacidil.
PindololEprosartan may increase the hypotensive activities of Pindolol.
PirfenidoneThe risk or severity of adverse effects can be increased when Eprosartan is combined with Pirfenidone.
PirlindolePirlindole may increase the hypotensive activities of Eprosartan.
PiroxicamThe risk or severity of adverse effects can be increased when Eprosartan is combined with Piroxicam.
PivhydrazinePivhydrazine may increase the hypotensive activities of Eprosartan.
PolythiazideEprosartan may increase the hypotensive activities of Polythiazide.
PrazosinPrazosin may increase the hypotensive activities of Eprosartan.
PrimidonePrimidone may increase the hypotensive activities of Eprosartan.
PropacetamolThe risk or severity of adverse effects can be increased when Eprosartan is combined with Propacetamol.
PropranololPropranolol may increase the hypotensive activities of Eprosartan.
PTC299The risk or severity of adverse effects can be increased when Eprosartan is combined with PTC299.
QuetiapineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Quetiapine.
QuinaprilEprosartan may increase the hypotensive activities of Quinapril.
QuinineQuinine may increase the hypotensive activities of Eprosartan.
RamiprilRamipril may increase the hypotensive activities of Eprosartan.
RasagilineRasagiline may increase the hypotensive activities of Eprosartan.
RemikirenRemikiren may increase the hypotensive activities of Eprosartan.
RescinnamineEprosartan may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Eprosartan.
ResveratrolThe risk or severity of adverse effects can be increased when Eprosartan is combined with Resveratrol.
ReviparinReviparin may increase the hyperkalemic activities of Eprosartan.
RiociguatEprosartan may increase the hypotensive activities of Riociguat.
RisperidoneEprosartan may increase the hypotensive activities of Risperidone.
RituximabEprosartan may increase the hypotensive activities of Rituximab.
RofecoxibThe risk or severity of adverse effects can be increased when Eprosartan is combined with Rofecoxib.
SafrazineSafrazine may increase the hypotensive activities of Eprosartan.
SalicylamideThe risk or severity of adverse effects can be increased when Eprosartan is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Eprosartan is combined with Salicylic acid.
SalsalateThe risk or severity of adverse effects can be increased when Eprosartan is combined with Salsalate.
SaprisartanEprosartan may increase the hypotensive activities of Saprisartan.
SecobarbitalSecobarbital may increase the hypotensive activities of Eprosartan.
SelegilineSelegiline may increase the hypotensive activities of Eprosartan.
SelexipagEprosartan may increase the hypotensive activities of Selexipag.
SeratrodastThe risk or severity of adverse effects can be increased when Eprosartan is combined with Seratrodast.
SildenafilSildenafil may increase the antihypertensive activities of Eprosartan.
SitaxentanEprosartan may increase the hypotensive activities of Sitaxentan.
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Eprosartan.
SpiraprilEprosartan may increase the hypotensive activities of Spirapril.
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Eprosartan.
SRT501The risk or severity of adverse effects can be increased when Eprosartan is combined with SRT501.
SulfasalazineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Sulfasalazine.
SulindacThe risk or severity of adverse effects can be increased when Eprosartan is combined with Sulindac.
SuprofenThe risk or severity of adverse effects can be increased when Eprosartan is combined with Suprofen.
TadalafilTadalafil may increase the antihypertensive activities of Eprosartan.
TelmisartanEprosartan may increase the hypotensive activities of Telmisartan.
TemocaprilEprosartan may increase the hypotensive activities of Temocapril.
TenoxicamThe risk or severity of adverse effects can be increased when Eprosartan is combined with Tenoxicam.
TepoxalinThe risk or severity of adverse effects can be increased when Eprosartan is combined with Tepoxalin.
TerazosinThe risk or severity of adverse effects can be increased when Eprosartan is combined with Terazosin.
TeriflunomideThe risk or severity of adverse effects can be increased when Eprosartan is combined with Teriflunomide.
TerlipressinEprosartan may increase the hypotensive activities of Terlipressin.
ThiamylalThiamylal may increase the hypotensive activities of Eprosartan.
ThiopentalThiopental may increase the hypotensive activities of Eprosartan.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Eprosartan is combined with Tiaprofenic acid.
TiboloneEprosartan may increase the hypotensive activities of Tibolone.
TicrynafenEprosartan may increase the hypotensive activities of Ticrynafen.
TimololTimolol may increase the hypotensive activities of Eprosartan.
TinzaparinTinzaparin may increase the hyperkalemic activities of Eprosartan.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Eprosartan.
TolazolineTolazoline may increase the hypotensive activities of Eprosartan.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Eprosartan is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Eprosartan is combined with Tolmetin.
ToloxatoneToloxatone may increase the hypotensive activities of Eprosartan.
TolvaptanTolvaptan may increase the hyperkalemic activities of Eprosartan.
TorasemideTorasemide may increase the hypotensive activities of Eprosartan.
TrandolaprilTrandolapril may increase the hypotensive activities of Eprosartan.
TranilastThe risk or severity of adverse effects can be increased when Eprosartan is combined with Tranilast.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Eprosartan.
TranylcypromineTranylcypromine may increase the hypotensive activities of Eprosartan.
TravoprostTravoprost may increase the hypotensive activities of Eprosartan.
TreprostinilTreprostinil may increase the hypotensive activities of Eprosartan.
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Eprosartan.
TrichlormethiazideEprosartan may increase the hypotensive activities of Trichlormethiazide.
TrimazosinEprosartan may increase the hypotensive activities of Trimazosin.
TrimethaphanEprosartan may increase the hypotensive activities of Trimethaphan.
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Eprosartan.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Eprosartan is combined with Trisalicylate-choline.
UdenafilUdenafil may increase the antihypertensive activities of Eprosartan.
UnoprostoneEprosartan may increase the hypotensive activities of Unoprostone.
ValdecoxibThe risk or severity of adverse effects can be increased when Eprosartan is combined with Valdecoxib.
ValsartanValsartan may increase the hypotensive activities of Eprosartan.
VardenafilVardenafil may increase the antihypertensive activities of Eprosartan.
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Eprosartan.
XylometazolineEprosartan may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Eprosartan.
ZaltoprofenThe risk or severity of adverse effects can be increased when Eprosartan is combined with Zaltoprofen.
ZileutonThe risk or severity of adverse effects can be increased when Eprosartan is combined with Zileuton.
ZomepiracThe risk or severity of adverse effects can be increased when Eprosartan is combined with Zomepirac.
Food Interactions
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
Receptor for angiotensin II. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.
Gene Name:
AGTR1
Uniprot ID:
P30556
Molecular Weight:
41060.53 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Heusser K, Vitkovsky J, Schmieder RE, Schobel HP: AT1 antagonism by eprosartan lowers heart rate variability and baroreflex gain. Auton Neurosci. 2003 Aug 29;107(1):45-51. [PubMed:12927226 ]
  3. Gremmler B, Kunert M, Schleiting H, Ulbricht LJ: Improvement of cardiac output in patients with severe heart failure by use of ACE-inhibitors combined with the AT1-antagonist eprosartan. Eur J Heart Fail. 2000 Jun;2(2):183-7. [PubMed:10856732 ]
  4. Suzuki G, Mishima T, Tanhehco EJ, Sharov VG, Todor A, Rostogi S, Gupta RC, Chaudhry PA, Anagnostopoulos PV, Nass O, Goldstein S, Sabbah HN: Effects of the AT1-receptor antagonist eprosartan on the progression of left ventricular dysfunction in dogs with heart failure. Br J Pharmacol. 2003 Jan;138(2):301-9. [PubMed:12540520 ]
  5. Ilson BE, Martin DE, Boike SC, Jorkasky DK: The effects of eprosartan, an angiotensin II AT1 receptor antagonist, on uric acid excretion in patients with mild to moderate essential hypertension. J Clin Pharmacol. 1998 May;38(5):437-41. [PubMed:9602957 ]
  6. Nap A, Mathy MJ, Balt JC, Pfaffendorf M, van Zwieten PA: Pre- and postsynaptic inhibitory potencies of the angiotensin AT1 receptor antagonists eprosartan and candesartan. Eur J Pharmacol. 2003 May 23;469(1-3):117-24. [PubMed:12782193 ]
  7. Hedner T: The clinical profile of the angiotensin II receptor blocker eprosartan. J Hypertens Suppl. 2002 Jun;20(5):S33-8. [PubMed:12184062 ]
  8. Puig JG, Lopez MA, Bueso TS, Bernardino JI, Jimenez RT: Clinical profile of eprosartan. Cardiovasc Drugs Ther. 2002 Dec;16(6):543-9. [PubMed:12766389 ]
  9. Ruilope L, Jager B: Eprosartan for the treatment of hypertension. Expert Opin Pharmacother. 2003 Jan;4(1):107-14. [PubMed:12517247 ]
  10. de la Sierra A, Ram CV: Introduction: The pharmacological profile of eprosartan--implications for cerebrovascular and cardiovascular risk reduction. Curr Med Res Opin. 2007 Nov;23 Suppl 5:S1-3. doi: 10.1185/030079907X260692. [PubMed:18093407 ]
  11. Murdoch DR, McDonagh TA, Farmer R, Morton JJ, McMurray JJ, Dargie HJ: ADEPT: Addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects. Am Heart J. 2001 May;141(5):800-7. [PubMed:11320369 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
References
  1. Weiss J, Sauer A, Divac N, Herzog M, Schwedhelm E, Boger RH, Haefeli WE, Benndorf RA: Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters. Biopharm Drug Dispos. 2010 Mar;31(2-3):150-61. doi: 10.1002/bdd.699. [PubMed:20222053 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23